{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Dapagliflozin",
        "type": {
          "id": "62f5cd0d-fc22-412f-a301-9a49b6d5f35e",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "6acf477f-0509-42d4-a0c7-d1f737e0e182",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "SGLT-2 inhibitor administered as an add-on to insulin therapy.",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Placebo",
        "type": {
          "id": "2fee2f28-1354-4ab6-9f32-03288a498d8c",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "aab1ac41-a386-4863-8d74-50a21f32d67b",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo tablets for dapagliflozin.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Insulin",
        "type": {
          "id": "15f97b53-d016-4b1a-adcd-209744b8e280",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "6069effb-46f1-4bfc-ad6f-003c236c73cb",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Ongoing insulin therapy (MDI or CSII) for Type 1 Diabetes Mellitus.",
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Acetaminophen/paracetamol",
        "type": {
          "id": "59421dfe-01e7-4046-87bd-936879c59321",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "72ea9843-d5cf-4a96-bfb0-7c658eb05fff",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited while using the CGM device and 24 hours prior to insertion.",
        "administrationIds": [
          "admin_4"
        ]
      },
      {
        "id": "int_5",
        "name": "Systemic corticosteroid therapy",
        "type": {
          "id": "9a4dc61b-50a9-417d-9559-1f0a3bfd0a85",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "292c547c-fe22-44e5-b0cd-8b87f3ecc981",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Newly initiated treatment involving 5 or more days is prohibited; chronic use (>4 weeks) is an exclusion criterion."
      },
      {
        "id": "int_6",
        "name": "Weight loss medication",
        "type": {
          "id": "76394ea2-2d70-42b6-a581-22fd49a1782a",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "4200b59c-ecc6-4039-9370-cc6adfa83703",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited for the duration of the study."
      },
      {
        "id": "int_7",
        "name": "Metformin",
        "type": {
          "id": "c891cad7-8c05-4eef-a081-b2f72a802114",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "ce47db5f-137a-47f8-804d-a35663a7b7e2",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Insulin-sensitizing agent; must be washed out 2 months prior to screening."
      },
      {
        "id": "int_8",
        "name": "GLP-1 receptor agonist",
        "type": {
          "id": "0066f065-28e4-486d-8ae5-70dbfdd7cb1f",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "0ae476be-a544-4f40-9fa2-dd60823f179d",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Must be washed out 1-2 months prior to screening depending on administration frequency."
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Dapagliflozin film-coated tablets",
        "administrableDoseForm": {
          "id": "810c066c-28a3-4f31-9cb5-5dde89041b5f",
          "code": "C42998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Tablet",
          "standardCode": {
            "id": "705a9b91-82db-4b8a-a7b8-c2b04ef11bf9",
            "code": "C42998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Tablet",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "59899959-c6ff-4e30-8ce2-33f42364183f",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "5 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "AstraZeneca AB"
      },
      {
        "id": "prod_2",
        "name": "Placebo for dapagliflozin",
        "administrableDoseForm": {
          "id": "2e83b3e0-a5c3-4281-8dd4-7f58ccde48e1",
          "code": "C42998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Tablet",
          "standardCode": {
            "id": "d1052b58-2581-44d7-b536-7b7f2c5e2e97",
            "code": "C42998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Tablet",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "28b9923f-2aa2-4d74-a3ec-843039328379",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "0 mg",
        "substanceIds": [
          "sub_2"
        ],
        "manufacturer": "AstraZeneca AB"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Dapagliflozin 5 mg regimen",
        "instanceType": "Administration",
        "dose": "5 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "52 weeks (24-week short-term + 28-week long-term)"
      },
      {
        "id": "admin_2",
        "name": "Dapagliflozin 10 mg regimen",
        "instanceType": "Administration",
        "dose": "10 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "52 weeks (24-week short-term + 28-week long-term)"
      },
      {
        "id": "admin_3",
        "name": "Placebo regimen",
        "instanceType": "Administration",
        "dose": "0 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "52 weeks"
      },
      {
        "id": "admin_4",
        "name": "Background Insulin",
        "instanceType": "Administration",
        "dose": "Adjustable (>= 0.3 U/kg/day)",
        "doseFrequency": "Varies (MDI >= 3 injections/day or CSII)",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "Continuous"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Dapagliflozin",
        "instanceType": "Substance",
        "description": "Selective inhibitor of sodium glucose cotransporter 2 (SGLT-2)"
      },
      {
        "id": "sub_2",
        "name": "Insulin",
        "instanceType": "Substance",
        "description": "Exogenous insulin for glycemic control"
      }
    ],
    "medicalDevices": [
      {
        "id": "dev_1",
        "name": "Continuous Glucose Monitoring (CGM) device",
        "instanceType": "MedicalDevice",
        "manufacturer": "Not specified"
      },
      {
        "id": "dev_2",
        "name": "Blood glucose and ketone meter",
        "instanceType": "MedicalDevice",
        "manufacturer": "Not specified"
      },
      {
        "id": "dev_3",
        "name": "Insulin Pump",
        "instanceType": "MedicalDevice",
        "manufacturer": "Not specified"
      }
    ],
    "summary": {
      "interventionCount": 8,
      "productCount": 2,
      "deviceCount": 3
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Dapagliflozin",
        "role": "Investigational Product",
        "description": "SGLT-2 inhibitor administered as an add-on to insulin therapy."
      },
      {
        "name": "Placebo",
        "role": "Placebo",
        "description": "Matching placebo tablets for dapagliflozin."
      },
      {
        "name": "Insulin",
        "role": "Background Therapy",
        "description": "Ongoing insulin therapy (MDI or CSII) for Type 1 Diabetes Mellitus."
      },
      {
        "name": "Acetaminophen/paracetamol",
        "role": "Concomitant Medication",
        "description": "Prohibited while using the CGM device and 24 hours prior to insertion."
      },
      {
        "name": "Systemic corticosteroid therapy",
        "role": "Concomitant Medication",
        "description": "Newly initiated treatment involving 5 or more days is prohibited; chronic use (>4 weeks) is an exclusion criterion."
      },
      {
        "name": "Weight loss medication",
        "role": "Concomitant Medication",
        "description": "Prohibited for the duration of the study."
      },
      {
        "name": "Metformin",
        "role": "Concomitant Medication",
        "description": "Insulin-sensitizing agent; must be washed out 2 months prior to screening."
      },
      {
        "name": "GLP-1 receptor agonist",
        "role": "Concomitant Medication",
        "description": "Must be washed out 1-2 months prior to screening depending on administration frequency."
      }
    ],
    "products": [
      {
        "name": "Dapagliflozin film-coated tablets",
        "doseForm": "Tablet",
        "strength": "5 mg",
        "manufacturer": "AstraZeneca AB"
      },
      {
        "name": "Placebo for dapagliflozin",
        "doseForm": "Tablet",
        "strength": "0 mg",
        "manufacturer": "AstraZeneca AB"
      }
    ],
    "substances": [
      {
        "name": "Dapagliflozin",
        "description": "Selective inhibitor of sodium glucose cotransporter 2 (SGLT-2)"
      },
      {
        "name": "Insulin",
        "description": "Exogenous insulin for glycemic control"
      }
    ],
    "administrations": [
      {
        "name": "Dapagliflozin 5 mg regimen",
        "dose": "5 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "52 weeks (24-week short-term + 28-week long-term)"
      },
      {
        "name": "Dapagliflozin 10 mg regimen",
        "dose": "10 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "52 weeks (24-week short-term + 28-week long-term)"
      },
      {
        "name": "Placebo regimen",
        "dose": "0 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "52 weeks"
      },
      {
        "name": "Background Insulin",
        "dose": "Adjustable (>= 0.3 U/kg/day)",
        "frequency": "Varies (MDI >= 3 injections/day or CSII)",
        "route": "Subcutaneous",
        "duration": "Continuous"
      }
    ],
    "devices": [
      {
        "name": "Continuous Glucose Monitoring (CGM) device",
        "manufacturer": "Not specified",
        "purpose": "Blinded monitoring of interstitial glucose levels"
      },
      {
        "name": "Blood glucose and ketone meter",
        "manufacturer": "Not specified",
        "purpose": "Self-monitoring of blood glucose and ketones for safety and DKA management"
      },
      {
        "name": "Insulin Pump",
        "manufacturer": "Not specified",
        "purpose": "Continuous subcutaneous insulin infusion (CSII)"
      }
    ]
  }
}